摘要
目的 :探讨PSA、fPSA双标记时间分辨荧光免疫分析 (DELFIA)技术在前列腺良恶性疾病诊断中的价值。方法 :采用双标记DELFIA检测 2 3例病理确诊的前列腺癌 (PCa) ,4 0例良性前列腺增生 (BPH)及30例正常对照血清PSA、fPSA水平 ,并与化学发光分析 (Immulite)比较。结果 :PSADELFIA测定结果PCa组(1 5 8 39± 92 5 5ng/ml)高于BPH组 (9 0 0± 1 0 6 1ng/ml)及对照组 (1 1 7± 0 6 9ng/ml) ,三组间比较有极显著性差异 (p <0 0 0 1 )。DELFIA与Immulite两种方法测定结果呈高度正相关关系 (r =0 95 4 ,p <0 0 0 1 )。PSADELFIA敏感性为 1 0 0 % ,特异性为 5 5 0 % ;Immulite敏感性为 1 0 0 % ,特异性为 4 7 5 %。fPSADELFIA测定结果PCa组 (73 8± 93 5 8ng/ml)高于BPH组 (1 5 8± 1 6 7ng/ml)及对照组 (0 31± 0 1 7ng/ml) ;三组间比较均有极显著性差异 (p <0 0 0 1 )。BPH组及对照组两种方法测定结果呈正相关关系 (r =0 94 ,p <0 0 0 1 ) ,PCa组两种方法测定结果亦呈正相关关系 (r =0 5 6 3,p <0 0 1 )。 结论 :PSA、fPSA双标记时间分辨荧光免疫分析一次检测可同时测出PSA及fPSA结果 。
Objective To investigate the diagnostic value of determination of serum PSA and fPSA levels with DELFIA in benign and malignant prostatic diseases. Methods Serum PSA and fPSA levels were determined with DELFIA in 23 cases of pathologically diagnosed prostatic carcinoma (PCa), 40 cases of benign prostatic hyperplasia (BPH) and 30 controls. The results were compared with those obtained by Immulite. Results With DELFIA, Serum PSA levels in PCa group, BPH group and controls were 158 39±92 55ng/ml, 9 00±0 61ng/ml and 1 17±0 69ng/ml respectively; differences between groups were very significant ( p <0 001). Results obtained by DELFIA and immulite were highly positively correlated ( r=0 594,p <0 001). Sensitivity was 100% and specificity 55% for DELFIA; vs 100% and 47 5% for Immulite. Also with DELFA, serum fPSA levels in PCa group, BPH group and controls were 73 8±93 58ng/ml, 1 57±1 67ng/ml and 0 31±0 17ng/ml respectively 3 differences between groups wre again very significant ( p <0 001). Results obtained by DELFIA and Immulite were positively correlated :( r=0 94,p <0 001 for BPH group and controls; ( r=0 563,p <0 01 for PCa group). Conclusion Both serum levels of PSA and fPSA can be obtained at same time with a single maneaver by DELFIA. This method is very sensitive for detection of prostatic carcinoma.
出处
《放射免疫学杂志》
CAS
2003年第6期382-384,共3页
Journal of Radioimmanology
